The primary endpoint was the proportion of participants with a viral load of less than @ copies per mL at week @ , based on a US Food and Drug Administration snapshot algorithm for the modified intention-to-treat population , which excluded major protocol violations ( prohibited resistance or not receiving a protease inhibitor at baseline ) .